ALFA Filings
Every announcement, straight from the exchange
Every Morepen Laboratories earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
3 announcements
Q2 FY27 revenue Rs755 Cr (+81%), PAT Rs89 Cr (+117%), EBITDA margin 17.45% (+897bps). H1 revenue Rs1,330 Cr (+57%). CDMO scale-up drives mix.
Morepen delivers explosive Q1'FY27 growth with 207% EBITDA jump, driven by the first commercial CDMO dispatches and operational leverage. The 'Morepen 2.0' strategy shifts focus from commodity APIs to high-margin innovation-led manufacturing.
Morepen Labs reported Q4 FY26 revenue of ₹472 Cr, up 22% YoY, while shifting focus toward long-term CDMO contracts and high-margin medical devices.